An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Trial Profile

An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2012

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Mar 2011 Actual end date changed from Dec 2011 to Mar 2011 as reported by ClinicalTrials.gov.
    • 25 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top